近日，据CDE官网公示，复星医药和Bial-Portela&Ca公司共同申报的5.1类新药奥吡卡朋胶囊的上市申请获得受理。资料显示，奥吡卡朋胶囊是一款复星医药从葡萄牙Bial-Portela&Ca公司引进的原发性帕金森病辅助治疗药物，为新一代的儿茶酚 ...

Geriatrics and Aging. 2008;11(4):215-222. Shen-Yang Lim, MBBS, FRACP, Movement Disorder Centre, University of Toronto, Toronto Western Hospital, Toronto, ON. Susan H ...

Nonmotor symptoms may appear during the course of Parkinson's disease, complicating the advanced phase in particular, but are also common in the premotor phase of Parkinson's disease. The ...

（1）托卡朋（Tolcapone）由罗氏、Valeant和Meda联合研发，是全球首款获批上市的COMT抑制剂，于1997年8月获EMA批准，之后于1998年1月获FDA批准上市，商品 ...